SCHEMBL32690365

SCHEMBL32690365

CS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)ncc1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 3/20 0.60
▸ ZAP70 P43403 1/20 0.59
▸ EGFR P00533 4/20 0.56
▸ MAPK9 P45984 3/20 0.55
▸ MAPK10 P53779 3/20 0.55
▸ ULK1 O75385 1/20 0.54
▸ IGF1R P08069 2/20 0.53
▸ MAPK8 P45983 1/20 0.53
▸ SYK P43405 2/20 0.52
▸ CCNK O75909 1/20 0.51
▸ CCNA2 P20248 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ CCND3 P30281 1/20 0.51
▸ CDK9 P50750 1/20 0.51
▸ CDK6 Q00534 1/20 0.51
▸ BRD4 O60885 1/20 0.51
▸ INSR P06213 1/20 0.49
▸ PTK2 Q05397 1/20 0.49
▸ PTK2B Q14289 1/20 0.49
▸ PKMYT1 Q99640 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31251185 0.82 ALK (0.63) ALKZAP70EGFRULK1IGF1R
SCHEMBL31251214 0.82 EGFR (0.61) ALKZAP70EGFRMAPK9MAPK10
SCHEMBL31251143 0.81 EGFR (0.60) ALKEGFRBRD4AURKAAURKB
SCHEMBL25002639 0.79 ALK (0.55) ALKEGFRULK1IGF1RCDK9
SCHEMBL31251253 0.78 IGF1R (0.66) ALKEGFRULK1IGF1RCCNK
SCHEMBL32690286 0.77 IGF1R (0.67) ALKEGFRMAPK9MAPK10ULK1
SCHEMBL32690393 0.76 PTK2 (0.54) ALKULK1IGF1RCDK9BRD4
SCHEMBL29747119 0.76 ZAP70 (0.56) ALKZAP70MAPK9MAPK10IGF1R
SCHEMBL29746768 0.76 ZAP70 (0.56) ALKZAP70MAPK9MAPK10IGF1R
SCHEMBL31251244 0.75 EGFR (0.85) ALKEGFRIGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085050-A1 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD (US) 2026-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085050-A1 TRIPLE KINASE INHIBITORS ALK, ERBB2, ERBB3 ALK 1/4885ZAP70 571/4885EGFR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback